Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biotecnol
London, England, United Kingdompitchbook.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Biotecnol develops bispecific antibody-based immunotherapies primarily in oncology. Its lead asset involving Cardiotrophin‑1 reached Phase 2 for myocardial reperfusion injury. Other pipeline assets include preclinical or pending-stage bispecifics and ADCs targeting various tumor antigens. Some infectious disease programs have been discontinued.[1][2][3]
- Therapeutic areas
- OncologyCardiovascularInfectious Diseases
- Modalities
- Bispecific antibodiesAntibody drug conjugates (ADC)Cytokines[2][3][4]
- Industry
- Biotech
02
Partnerships
PolyTherics (collaboration on ThioBridge ADC technology)[3]
Beyond the preview
Go deeper on Biotecnol.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biotecnol.